No Data
FDA Grants Breakthrough Device Designation for SeaStar Medical's Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis
Express News | FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis
Express News | Economic Analysis Supporting Significant Hospitalization Cost Reduction With SeaStar Medical’s Quelimmune Pediatric Therapeutic Device Presented at Asn Kidney Week 2024 - Update
Express News | Nuwellis Inc - on October 20, Co and SeaStar Medical Holding Entered Into Confidential Settlement Agreement and Release
SeaStar Medical Announces That Stanford Medicine Is Cleared To Actively Enroll Subjects In The NEUTRALIZE-AKI Adult Acute Kidney Injury Pivotal Trial
SeaStar Medical Holding Assumed All Responsibility For Direct Sales, Marketing And Distribution Of QUELIMMUNE To Hospital Customers
No Data
No Data